Lysogeny and bacteriophage host range within the Burkholderia cepacia complex

被引:37
作者
Langley, R
Kenna, DT
Vandamme, P
Ure, R
Govan, JRW
机构
[1] Univ Edinburgh, Dept Med Microbiol, Edinburgh EH8 9AG, Midlothian, Scotland
[2] State Univ Ghent, Fac Wetenschappen, Mikrobiol Lab, B-9000 Ghent, Belgium
关键词
D O I
10.1099/jmm.0.05099-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Burkholderia cepacia complex comprises a group of nine closely related species that have emerged as life-threatening pulmonary pathogens in immunocompromised patients, particularly individuals with cystic fibrosis or chronic granulomatous disease. Attempts to explain the genomic plasticity, adaptability and virulence of the complex have paid little attention to bacteriophages, particularly the potential contribution of lysogenic conversion and transduction. In this study, lysogeny was observed in 10 of 20 representative strains of the B. cepacia complex. Three temperate phages and five lytic phages isolated from soils, river sediments or the plant rhizosphere were chosen for further study. Six phages exhibited T-even morphology and two were lambda-like. The host range of individual phages, when tested against 66 strains of the B. cepacia complex and a representative panel of other pseudomonads, was not species-specific within the B. cepacia complex and, in some phages, included Burkholderia gladioli and Pseudomonas aeruginosa. These new data indicate a potential role for phages of the B. cepacia complex in the evolution of these soil bacteria as pathogens of plants, humans and animals, and as novel therapeutic agents.
引用
收藏
页码:483 / 490
页数:8
相关论文
共 49 条
[21]   Lack of correlation between O-serotype, bacteriophage susceptibility and genomovar status in the Burkholderia cepacia complex [J].
Kenna, DT ;
Barcus, VA ;
Langley, RJ ;
Vandamme, P ;
Govan, JRW .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2003, 35 (02) :87-92
[22]   Genomic complexity and plasticity of Burkholderia cepacia [J].
Lessie, TG ;
Hendrickson, W ;
Manning, BD ;
Devereux, R .
FEMS MICROBIOLOGY LETTERS, 1996, 144 (2-3) :117-128
[23]   INVITRO ACTIVITIES OF MEROPENEM, PD-127391, PD-131628, CEFTAZIDIME, CHLORAMPHENICOL, COTRIMOXAZOLE, AND CIPROFLOXACIN AGAINST PSEUDOMONAS-CEPACIA [J].
LEWIN, C ;
DOHERTY, C ;
GOVAN, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (01) :123-125
[24]   Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis [J].
LiPuma, JJ ;
Spilker, T ;
Gill, LH ;
Campbell, PW ;
Liu, LX ;
Mahenthiralingam, E .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (01) :92-96
[25]   Burkholderia cepacia - Management issues and new insights [J].
LiPuma, JJ .
CLINICS IN CHEST MEDICINE, 1998, 19 (03) :473-+
[26]   Commercial use of Burkholderia cepacia [J].
LiPuma, JJ ;
Mahenthiralingam, E .
EMERGING INFECTIOUS DISEASES, 1999, 5 (02) :305-306
[27]  
LIPUMA JJ, 2000, PEDIATR PULM, V20, P288
[28]   The detection of insertion sequences within the human pathogen Burkholderia pseudomallei which have been identified previously in Burkholderia cepacia [J].
Mack, K ;
Titball, RW .
FEMS MICROBIOLOGY LETTERS, 1998, 162 (01) :69-74
[29]   DNA-based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III [J].
Mahenthiralingam, E ;
Bischof, J ;
Byrne, SK ;
Radomski, C ;
Davies, JE ;
Av-Gay, Y ;
Vandamme, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3165-3173
[30]   Burkholderia cepacia complex infection in patients with cystic fibrosis [J].
Mahenthiralingam, E ;
Baldwin, A ;
Vandamme, P .
JOURNAL OF MEDICAL MICROBIOLOGY, 2002, 51 (07) :533-538